education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Advertisement
Advertisement
MIMS home
Drugs
Info
Mefinter
Mefinter
mefenamic acid
Manufacturer:
Interbat
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Mefenamic acid
Indications/Uses
Fever, toothache, myalgia, earache, rheumatic traumatic & post-op pain, bursitis, dysmenorrhea.
Dosage/Direction for Use
Adult & childn >14 yr
Initially 500 mg, then 250 mg 6 hrly. Max: 7 days.
Administration
Should be taken with food: Take immediately after meals.
Contraindications
Peptic or intestinal ulceration, inflammatory bowel disease. Renal or hepatic impairment.
Special Precautions
Dehydration, epilepsy, asthma. Pregnancy.
Adverse Reactions
GI disturbances & bleeding, peptic ulceration; headache, drowsiness, dizziness, nervousness; visual disturbances, skin rashes, blood dyscrasias, nephropathy.
View
ADR Reporting Link
Drug Interactions
Oral anticoagulants.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.
Regulatory Classification
K
Presentation/Packing
Form
Mefinter cap 250 mg
Packing/Price
10 × 10's
Form
Mefinter cap 500 mg
Packing/Price
10 × 10's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk